Holen Sie sich die Stockscreener-App
57.54
2.90%
1.62
Handel nachbörslich:
57.70
0.16
+0.28%
Schlusskurs vom Vortag:
$55.92
Offen:
$56.05
24-Stunden-Volumen:
1.04M
Relative Volume:
0.42
Marktkapitalisierung:
$7.09B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
19.05
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+1.66%
1M Leistung:
+8.96%
6M Leistung:
+4.09%
1J Leistung:
+5.89%
1-Tages-Spanne:
$56.05
$57.77
1-Wochen-Bereich:
$55.64
$58.56
52-Wochen-Spanne:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
57.54 | 6.97B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
What analysts say about Halozyme Therapeutics Inc. stockConsistently exceptional gains - jammulinksnews.com
What drives Halozyme Therapeutics Inc. stock pricePhenomenal trading returns - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance
Halozyme to Report Second Quarter 2025 Financial and Operating Results - 富途牛牛
Halozyme Therapeutics Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest
Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru
Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest
Halozyme Therapeutics' strategic adoption - MarketScreener
Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest
Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha
Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria
Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada
Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress
Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN
Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus
Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest
Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa
Halozyme therapeutics added to Russell 1000 index - Investing.com
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve
Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan
Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):